Shearman & Sterling advised Boston Scientific Corporation, as borrower on (i) a $1.25 billion unsecured 364-day term loan facility agented by The Bank of Nova Scotia to repay existing short term indebtedness and finance working capital and general corporate needs, (ii) an amendment to its existing $2.75 billion unsecured revolving facility agented by Wells Fargo, National Association and (iii) an amendment to its existing $1 billion unsecured 364-day term loan facility. 

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular.

The Team